Does starting allopurinol during acute gout attack prolonged the current episode? A double blinded randomized controlled trial

Faculty of Medicine Chiang Mai University0 个研究点目标入组 68 人开始时间: 2023年7月14日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Age 20 to 70 years
•2. Crystal proven gout or meet American College of Rheumatology/European League Against Rheumatism 2015 classification criteria for gout
•3. Onset of attack within 72 hours with at pain score determined by visual analog scale (VAS) of 4 or more
•4. Meet at least 1 criterion for uric lowering therapy, which include:
•- Gout with subcutaneous tophi(s)
•- Evidence of radiologic damage by any radiologic modalities
•- Patients with frequent flare (2 times or more/year)
•- Patients experiencing first flare with chronic kidney disease stage 3 or more, serum uric acid > 9 mg/dL or urolithiasis

•1. eGFR <30 ml/min/1.73 sq. m.
•2. Currently using urate lowering therapy (allopurinol, febuxostat, probenecid, benzbromarone, and sulfinpyrazone) or history of using it within the past 30 days.having uric lowering therapy treatment or history of using one in the past 30 days.
•3. History of allopurinol hypersensitivity syndrome
•4. Received drugs for acute treatment (NSAIDs, colchicine, or corticosteroids) for > 48 hours period
•5. Uncontrolled infection/severe sepsis or have any disease that the investigators consider that the patient might not be suitable for the study
•6. Poor controlled diabetes mellitus (HbA1c equal to or more than 8%)
•7. Active cancer
•8. Unable to communicate or perform visual analog scale/patient global assessment
•9. Unable to take oral medication
•10. Elevation of liver enzymes (AST/ALT) more thatn to times normal

发起方